In the previous couple of months, I’ve discovered extra firms, and at this time, I’m sharing the brand new record of 10 with you. As at all times – please ship me your recommendations and I’ll embrace them within the subsequent overview. The standards for this record are the next:
– Related to stem cell analysis, regenerative drugs, cell remedy, gene remedy area (therapeutic, instruments, reagents, service);
– New (Zero-5 years of existence) or comparatively new, however under-appreciated and broadly unknown;
– Very distinctive strategy/ new platform
1. Harvard Apparatus Regenerative Technology
HART is exclusive, public, clinical-stage firm, which commercialized instruments for complete organ bioengineering. Right now, HART is manufacturing “scaffolds, bioreactors and other tools for synthetic trachea” and supporting scientific trials. It can be attention-grabbing to observe if HART can transfer from hole organs to strong organs.
2. CRISPR Therapeutics
Very new startup with stellar group of scientific founders. The firm is commercializing new genome modifying know-how – CRISPR-Cas9 for remedy of genetic illnesses. The firm just lately raised $25M from VC.
three. Regenovo Biotechnology
“Chinese Organovo” – new bioprinting firm. They developed their very own bioprinter.
four. Cynata Therapeutics
Public, preclinical-stage Australian firm, commercializing giant scale manufacturing of iPS cell-derived mesenchymoangioblasts and MSCs (Cymerus platform) for therapeutic use.
Unique supplier of cell remedy logistics and cell merchandise monitoring. TrakCel platform synchronizes affected person information, manufacturing, storage and complete logistics chain.
6. Cyfuse Biomedical
New Japanese bioprinting startup. Cyfuse’s robotic platform “Regenova” is on a marketplace for R&D. Earlier this 12 months, Cyfuse shared their plans to enter scientific trails with bioprinted blood vessels.
Portuguese preclinical-stage startup, growing MSC-based therapies. Unlike different “MSC companies”, Cell2B is targeted solely on immune/ inflammatory circumstances. I feel, they’re representing the 2nd technology of “MSC companies”.
eight. Angiocrine Bioscience
Very new startup, spin-off from Weill-Cornell Medical College (Shahin Rafii). The firm commercializes “endothelial niche cells” for stem cells and most cancers cells enlargement in analysis. Very distinctive know-how with spectacular outcomes!
9. Platelet BioGenesis
New distinctive startup, which makes use of microfluidics chip know-how for scalable manufacturing of human therapeutic platelets.
Biomatrica develops CellStable platform, which “enable cell-based therapy through ambient biopreservation”. The firm gives distinctive different to cell cryopreservation – storage in dry ambient circumstances for weeks.
Disclaimer: This record displays solely my opinion and sympathy. I’ve no monetary curiosity in firms, talked about on this put up. This put up shouldn’t be thought-about as monetary recommendation.